Cargando…

The classical and alternative circulating renin‐angiotensin system in normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease

BACKGROUND: The behavior of the comprehensive circulating renin‐angiotensin system (RAS) in dogs with myxomatous mitral valve disease (MMVD) before to the onset of congestive heart failure remains largely unexplored. HYPOTHESIS/OBJECTIVES: The classical and alternative RAS activity and aldosterone c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hammond, Hillary H., Ames, Marisa K., Domenig, Oliver, Scansen, Brian A., Yang, Nuen Tsang, Wilson, Machelle D., Sunshine, Erin, Brunk, Kaitlyn, Masters, Allison
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2023
Materias:	SMALL ANIMAL
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229370/ https://www.ncbi.nlm.nih.gov/pubmed/36951394 http://dx.doi.org/10.1111/jvim.16687

Ejemplares similares

Echocardiographic Estimates of Right Ventricular Systolic Function in Dogs with Myxomatous Mitral Valve Disease
por: Chapel, E.H., et al.
Publicado: (2017)

Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease
por: Kim, H.‐S., et al.
Publicado: (2016)

The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs
por: Vezzosi, Tommaso, et al.
Publicado: (2021)

Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs
por: Nakamura, K., et al.
Publicado: (2017)

Prevalence and risk factors for atrial fibrillation in dogs with myxomatous mitral valve disease
por: Guglielmini, Carlo, et al.
Publicado: (2020)

Radiographic quantification of left atrial size in dogs with myxomatous mitral valve disease
por: Lam, Christopher, et al.
Publicado: (2021)

Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease
por: McManamey, Anna K., et al.
Publicado: (2023)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020)

Echocardiographic predictors of first onset of atrial fibrillation in dogs with myxomatous mitral valve disease
por: Baron Toaldo, Marco, et al.
Publicado: (2020)

Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease
por: Druzhaeva, Natalia, et al.
Publicado: (2021)

Echocardiographic estimation of left ventricular‐arterial coupling in dogs with myxomatous mitral valve disease
por: Osuga, Tatsuyuki, et al.
Publicado: (2021)

Prognostic value of serum cystatin C concentration in dogs with myxomatous mitral valve disease
por: Iwasa, Naoki, et al.
Publicado: (2023)

Changes in renin‐angiotensin‐aldosterone system during cardiac remodeling after mitral valvuloplasty in dogs
por: Cheng, Chieh‐Jen, et al.
Publicado: (2022)

Prognostic Value of Right Ventricular Tei Index in Dogs with Myxomatous Mitral Valvular Heart Disease
por: Nakamura, K., et al.
Publicado: (2016)

Reproducibility of echocardiographic indices of left atrial size in dogs with subclinical myxomatous mitral valve disease
por: Hsue, Weihow, et al.
Publicado: (2020)

Assessment of Left Atrial Deformation and Function by 2‐Dimensional Speckle Tracking Echocardiography in Healthy Dogs and Dogs With Myxomatous Mitral Valve Disease
por: Baron Toaldo, M., et al.
Publicado: (2017)

Effect of calcifediol supplementation on renin‐angiotensin‐aldosterone system mediators in dogs with chronic kidney disease
por: Miller, Matthew, et al.
Publicado: (2022)

Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease
por: Tidholm, A., et al.
Publicado: (2015)

Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease
por: Baron Toaldo, Marco, et al.
Publicado: (2018)

Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study
por: Boswood, Adrian, et al.
Publicado: (2020)

The Renin‐Angiotensin‐Aldosterone System in Greyhounds and Non‐Greyhound Dogs
por: Martinez, J., et al.
Publicado: (2017)

Utility of radiographic measurements to predict echocardiographic left heart enlargement in dogs with preclinical myxomatous mitral valve disease
por: Poad, Megan H., et al.
Publicado: (2020)

Prognostic value of left ventricular‐arterial coupling estimated using echocardiography in dogs with myxomatous mitral valve disease
por: Osuga, Tatsuyuki, et al.
Publicado: (2021)

Prognostic value of pulmonary vascular resistance estimated by echocardiography in dogs with myxomatous mitral valve disease and pulmonary hypertension
por: Yuchi, Yunosuke, et al.
Publicado: (2023)

Radiographic lung congestion scores in dogs with acute congestive heart failure caused by myxomatous mitral valve disease
por: Koster, Liza, et al.
Publicado: (2023)

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial
por: Boswood, A., et al.
Publicado: (2016)

Real‐Time 3‐Dimensional Echocardiographic Assessment of Effective Regurgitant Orifice Area in Dogs With Myxomatous Mitral Valve Disease
por: Tidholm, A., et al.
Publicado: (2017)

Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration
por: Reimann, M.J., et al.
Publicado: (2017)

Prevalence of aldosterone breakthrough in dogs receiving renin‐angiotensin system inhibitors for proteinuric chronic kidney disease
por: Ames, Marisa K., et al.
Publicado: (2022)

Atrial Fibrillation as a Prognostic Indicator in Medium to Large‐Sized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure
por: Jung, S.W., et al.
Publicado: (2016)

Evaluation of urinary neutrophil gelatinase‐associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease
por: Troia, Roberta, et al.
Publicado: (2022)

Influence of concurrent lower respiratory tract disease on point‐of‐care lung ultrasound in small‐breed dogs with myxomatous mitral valve disease
por: Lam, Man‐Cham, et al.
Publicado: (2022)

Cardiorenal and endocrine effects of synthetic canine BNP1‐32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease
por: Yata, Mariko, et al.
Publicado: (2019)

Utility of Tissue Doppler Imaging in the Echocardiographic Evaluation of Left and Right Ventricular Function in Dogs with Myxomatous Mitral Valve Disease with or without Pulmonary Hypertension
por: Baron Toaldo, M., et al.
Publicado: (2016)

Effect of standard‐dose and high‐dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease
por: Kaplan, Joanna L., et al.
Publicado: (2022)

Comparison between real‐time 3‐dimensional and 2‐dimensional biplane echocardiographic assessment of left atrial volumes in dogs with myxomatous mitral valve disease
por: Tidholm, Anna, et al.
Publicado: (2019)

Effect of prespecified therapy escalation on plasma NT‐proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease
por: Hezzell, Melanie J., et al.
Publicado: (2018)

A prospective, randomized, double‐blind, placebo‐controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease
por: Newhard, Daniel K., et al.
Publicado: (2018)

Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST)
por: Coffman, Melissa, et al.
Publicado: (2021)

The renin‐angiotensin‐aldosterone system and its suppression
por: Ames, Marisa K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0q4bbdcab2gp5hjk1iskjv8qm0